Sinotau is focusing in products for cancer, cardiovascular and neurodegenerative diseases, concentrating resources on the development of innovative products and building up a solid and winning pipeline. The plan is to develop PET, SPECT, radionuclide therapy, molecular imaging among other nuclear medicine procedures in China in the next decade covering isotopes such as 18F, 13C, 14C, 99mTc, 68Ga, 177Lu, 131I, 123I, 124I.
Sinotau has also oriented its efforts on in-house R&D for biologics. We have an antibody R&D center in the city of Birmingham in the U.S. state of Alabama, taking full advantage of the company access to both Chinese and American laboratories.
Early research and development of innovative biopharmaceuticals, such as conjugated drugs, and the use of radiopharmaceutical research and development platforms to combine biological antibodies with radionuclides to provide a more direct and simple treatment strategy for the treatment of tumors.
Sinotau has extensive and robust R&D capabilities but is also building a strong network with prestigious academic players in China.
Sinotau have established a joint R&D center with the Institute of Radiation Medicine Chinese Academy of Medical Sciences to conduct a series of strategic collaborations in radiopharmaceutical R&D, and market application. At the same time, Sinotau maintains a close cooperation for radiopharmaceuticals, chemical drugs, pharmacology and clinical studies with other prestigious domestic organizations such as Peking University Health Science Center, Beijing Normal University Drug Research Center, Center for Molecular Imaging at Xiamen University, Radiologic Department at Beijing Institute of Technology, Peking Union Medical College Hospital, Fuwai Cardiovascular Hospital, Beijing Xuanwu Hospital, Beijing Tiantan Hospital and other leading scientific research institutions.